29 results  save search


hal-02158538v1  Journal articles
Pierre-Michel LlorcaChristophe LançonOlivier BlancIngrid de ChazeronLudovic Samalin et al.  A composite scale applied to evaluate anxiety in schizophrenic patients (SAES)
European Archives of Psychiatry and Clinical Neuroscience, Springer Verlag, 2014, 264 (2), pp.171-178. ⟨10.1007/s00406-013-0416-1⟩
hal-02158481v1  Journal articles
Ludovic SamalinIngrid de ChazeronMaria ReinaresC. TorrentC. D. M Bonnin et al.  Euthymia is not always euthymia: Clinical status of bipolar patients after 6 months of clinical remission
European Psychiatry, Elsevier, 2016, Abstracts of the 24th European Congress of Psychiatry, 33 (Supplement), pp.S125. ⟨10.1016/j.eurpsy.2016.01.168⟩
hal-02173515v1  Journal articles
Ludovic SamalinFrank BellivierBruno GiordanaLiova YonVanessa Milhiet et al.  Patients’ Perspectives on Residual Symptoms in Bipolar Disorder
Journal of Nervous and Mental Disease, Lippincott, Williams & Wilkins, 2014, 202 (7), pp.550-555. ⟨10.1097/NMD.0000000000000157⟩
hal-02173576v1  Journal articles
Ricardo GarayLudovic SamalinAhcene HamegPierre-Michel Llorca. Investigational drugs for anxiety in patients with schizophrenia
Expert Opinion on Investigational Drugs, Taylor & Francis, 2015, 24 (4), pp.507-517. ⟨10.1517/13543784.2014.987339⟩
hal-02174589v1  Journal articles
Ricardo GarayMichel BourinEvelyne de PailletteLudovic SamalinAhcene Hameg et al.  Potential serotonergic agents for the treatment of schizophrenia
Expert Opinion on Investigational Drugs, Taylor & Francis, 2016, 25 (2), pp.159-170. ⟨10.1517/13543784.2016.1121995⟩
hal-02173552v1  Journal articles
Ludovic SamalinAurore TremeyPierre-Michel Llorca. Quetiapine extended release for the treatment of bipolar disorder
Expert Review of Neurotherapeutics, Expert Reviews (formerly Future Drugs), 2014, 14 (9), pp.987-1005. ⟨10.1586/14737175.2014.946407⟩